FDA Extends Dapagliflozin Indication Across LVEF Spectrum
The expanded approval is based on the positive results from DELIVER and mirrors last year’s decision for empagliflozin.
Related Articles
VibeRide | World’s First Longboard Brake
Welcome to VibeRide, home of the longboard brake. We’re group of guys from Salt Lake City who’s love of downhill skating sparked the idea for…
VibeRide | World’s First Longboard Brake
Welcome to VibeRide, home of the longboard brake. We’re group of guys from Salt Lake City who’s love of downhill skating sparked the idea for…
Beyond the Data: The Evolving Realm of Nurse Practitioners
Carys Barton and Donna Fitzsimons discuss training, regulation, and a focus on patient care as ANPs take on new roles.
Beyond the Data: The Evolving Realm of Nurse Practitioners
Carys Barton and Donna Fitzsimons discuss training, regulation, and a focus on patient care as ANPs take on new roles.
Beyond the Data: The Evolving Realm of Nurse Practitioners
Carys Barton and Donna Fitzsimons discuss training, regulation, and a focus on patient care as ANPs take on new roles.
Beyond the Data: Colchicine for Post-Op Atrial Fibrillation in COP-AF
David Conen walks Mamas Mamas through the trial results and what they mean for arrhythmia management following thoracic surgery.
Beyond the Data: Colchicine for Post-Op Atrial Fibrillation in COP-AF
David Conen walks Mamas Mamas through the trial results and what they mean for arrhythmia management following thoracic surgery.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex.…
Using National Databases for Research: The Good and the Bad
The NIS and NRD offer convenient data sources for fellows starting out in research—just don’t overlook other opportunities.
USPSTF: Screening Kids for Lipid Disorders Still Needs More Data
For the third time in 15 years, the task force has given an “I” recommendation to screening, citing not enough research.
